Scantox, together with its majority owner Impilo, has completed the acquisition of QPS Neuropharmacology, a leading contract research company specializing in neurodegenerative diseases, rare diseases, and mental disorders. The company, now known as Scantox Neuro, is known for its high-quality, scientifically-based services and has a proven track record in serving a loyal and broad customer base worldwide. With the acquisition of QPS Neuropharmacology, Scantox’s value chain is significantly expanded with unique and market-leading research capabilities in the field of the central nervous system (CNS).
QPS Neuropharmacology, founded in 1999, has a long history of developing expertise in lead optimization and efficacy studies. The company has a state-of-the-art 2,700-square-meter facility in Grambach, Austria, and employs over 80 staff members. With on-site availability of validated transgenic and non-transgenic in vitro and in vivo models, the company addresses multiple targets in the emerging CNS field and is an outstanding drug development partner for biotech and pharmaceutical companies.
„This is a transformative addition to our Discovery department that is fundamentally changing our lead optimization platform and expanding the depth and breadth of our services in the CNS and rare diseases. We will continue Scantox’s rapid growth trajectory and provide our customers worldwide with a continuously improved level of service quality and scientific excellence,“ says Jeanet Løgsted, CEO of Scantox Group.
Manuela Prokesch, Head of Scantox Neuro GmbH, adds, „Being part of the Scantox Group opens up unique opportunities for us to offer our customers an even broader range of services. As a company, we look forward to integrating into a highly trusted and recognized European contract research organization, where we can leverage synergies and pursue a common growth path.“
With the addition of the new company Neuro, the Scantox Group will employ over 300 staff members at six locations, offering services in lead optimization, regulatory toxicology, and CMC/Analytics.
Nicholas Hooge, Partner at Impilo, summarizes, „With the completion of this acquisition, Scantox can significantly expand its range of services and customer reach. We warmly welcome the Austrian team to the Scantox Group and see promising growth opportunities for the combined company in the future.“
Quelle: Scantox A / ots
